Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 389 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GI Cancer Clear all
Recruiting Phase 1 Interventional

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT07337525
View directory record Official record
Conditions
Advanced Malignant Solid Tumor, Solid Tumor Cancer
Interventions
PLT012
Drug
Lead sponsor
Pilatus Biosciences Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

NCT05121038
View directory record Official record
Conditions
Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions
CEND-1, Panitumumab, Folfirinox
Drug
Lead sponsor
Anup Kasi
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 7, 2026, 10:03 PM EDT
Completed No phase listed Observational

CryoSpray Ablation (TM) GI Patient Registry

NCT00747448
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Not listed
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 7, 2026, 10:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Patritumab deruxtecan
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Santa Monica, California • Aurora, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas

NCT00020345
View directory record Official record
Conditions
Stage IVA Pancreatic Cancer, Stage III Pancreatic Cancer, Adenocarcinoma of the Pancreas
Interventions
fluorouracil, gemcitabine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Timeline
2000 – 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 7, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

NCT00012246
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 7, 2026, 10:03 PM EDT
Completed No phase listed Observational

Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy.

NCT02909062
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Electronic Activity Monitoring (EAM), Daily Questionnaire
Device · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib and Nivolumab for Carcinoid Tumors

NCT04197310
View directory record Official record
Conditions
Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
Interventions
Nivolumab, Cabozantinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers

NCT03528863
View directory record Official record
Conditions
Caregiver, Metastatic Gastrointestinal Carcinoma
Interventions
Online Mindfulness Meditation, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 7, 2026, 10:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

NCT06055439
View directory record Official record
Conditions
Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
Interventions
CHM-2101 CAR-T cells
Biological
Lead sponsor
Chimeric Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery

NCT02511821
View directory record Official record
Conditions
Stage I Adult Liver Cancer, Stage I Colorectal Cancer, Stage IA Gastric Cancer, Stage IA Pancreatic Cancer, Stage IB Gastric Cancer, Stage IB Pancreatic Cancer, Stage II Adult Liver Cancer, Stage IIA Colorectal Cancer, Stage IIA Gastric Cancer, Stage IIA Pancreatic Cancer, Stage IIB Colorectal Cancer, Stage IIB Gastric Cancer, Stage IIB Pancreatic Cancer, Stage IIC Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Adult Liver Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Adult Liver Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Adult Liver Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer, Stage IVA Colorectal Cancer, Stage IVA Liver Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Liver Cancer, Stage IVB Pancreatic Cancer
Interventions
Computer-Assisted Intervention, Vivofit watch, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Not applicable Interventional

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

NCT04802486
View directory record Official record
Conditions
Cachexia, Weight Loss, Gastrointestinal Cancer
Interventions
EXCAP©®
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 7, 2026, 10:03 PM EDT
Completed No phase listed Observational

Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract

NCT01770405
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer, Pancreatic Islet Cell Tumors, Lymph Node Mass, Lymphadenopathy, GIST
Interventions
Endoscopic ultrasound fine needle aspiration
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors

NCT00081848
View directory record Official record
Conditions
Liver Neoplasms
Interventions
rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF, Celecoxib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 10:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Not applicable Interventional Results available

Improving Informed Consent for Palliative Chemotherapy

NCT02282722
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions
Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 7, 2026, 10:03 PM EDT
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2015 · Synced Sep 7, 2026, 10:03 PM EDT
Recruiting Not applicable Interventional

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

NCT05780684
View directory record Official record
Conditions
Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer, Ampullary Cancer
Interventions
FOX dose-escalation algorithm
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

NCT01264705
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 7, 2026, 10:03 PM EDT
Not listed No phase listed Observational

Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study

NCT05051358
View directory record Official record
Conditions
Therapeutic Endoscopic Ultrasound, Advanced Endoscopy, Therapeutic Endoscopy, Interventional Endoscopy, Interventional Endoscopic Ultrasound, Gastro-Intestinal Disorder, Gastrointestinal Disease, Gastrointestinal Cancer, Gastrointestinal Dysfunction, Gastrointestinal Fistula, Gastrointestinal Infection, Gastrointestinal Injury, Pancreatic Disease, Bile Duct Diseases
Interventions
Therapeutic Endoscopic Ultrasound
Procedure
Lead sponsor
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 7, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

NCT05789485
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
structured treadmill walking
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 10:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798
View directory record Official record
Conditions
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 10:03 PM EDT